Prognosis and Survival in Canine Hepatocellular Carcinoma

Prognosis in canine HCC is influenced by factors such as tumor subtype and location within the liver, particularly because these factors affect whether the tumor can be surgically removed. Surgical resectability is one of the most important considerations in determining outcome.

To learn more about treatment approaches and when they may be considered, see our Treatment Options page.

Because available studies often include small numbers of dogs and may involve differences in tumor characteristics, disease extent, and patient selection, interpreting survival data can be complex.

Surgical Outcomes

Surgical removal is commonly considered when tumors are determined to be resectable. In dogs with resectable tumors, surgical removal has been associated with prolonged survival times.^{Liptak et al.}

Tumor characteristics can influence whether surgical removal is feasible. Hepatocellular carcinomas are commonly classified as massive, nodular, or diffuse based on their distribution within the liver.^{Patnaik et al.} Tumors classified as the massive subtype are often more localized within the liver and may be considered for surgical removal, whereas nodular and diffuse subtypes more commonly involve multiple areas of the liver, which can limit the feasibility of surgical resection.^{Marconato et al.}

Tumor location within the liver may also be associated with differences in surgical risk. In one study, dogs with tumors located in the right middle liver lobe had an increased risk of death before discharge.^{Moyer et al.} This finding is consistent with earlier reports of increased intraoperative mortality associated with right-sided liver tumors, likely due to technical challenges related to vascular anatomy.^{Liptak et al.}

It is important to note that published surgical outcome data typically reflects dogs that were selected for surgery. These cases may differ from dogs with more advanced or unresectable disease, and outcomes reported in the literature may not apply to all patients.

In some cases where complete tumor removal may carry a high surgical risk, partial removal (debulking) may be considered as an alternative approach. This strategy may be used when a more aggressive surgery is likely to increase the risk of complications.^{Moyer et al.}

Conservative Management / Unresectable Tumors

Published survival times for dogs managed without surgery vary across studies.

In one study, dogs managed conservatively without surgery had a median survival time (MST) of approximately 270 days.^{Liptak et al.} In another study that included dogs whose tumors were considered unresectable and who underwent biopsy alone, a median survival time of 695 days was reported.^{Moyer et al.}

These differences highlight the variability between study populations and underscore that reported survival times may not be directly comparable across studies or representative of all dogs with unresectable tumors. Differences in extent of disease, overall health, case selection, and the type of supportive care provided may influence reported outcomes.

Systemic Therapy Outcomes

In cases where surgery is not an option, veterinary oncologists may consider systemic therapies. However, published evidence evaluating these treatments for canine HCC remains limited.

In a prospective study of dogs with HCC, treatment with sorafenib was associated with a longer time to progression compared with a metronomic chemotherapy protocol.^{Marconato et al.} In that study, dogs treated with sorafenib had a median survival time of 361 days, compared with 32 days in dogs receiving metronomic chemotherapy. These findings suggest that sorafenib may slow disease progression in some dogs, though the results are based on a small study population and may not be generalizable to all dogs.

Systemic therapies are generally not considered curative, and their role in the management of canine HCC continues to be studied.

Ongoing research continues to explore new treatment approaches for canine HCC. For more information on emerging therapies and clinical studies, see our Clinical Trials page, or visit our Studies and Articles page for published research.

Important Considerations

Canine HCC is relatively uncommon, and much of the available research is based on retrospective studies or small case series. As a result, reported outcomes may not fully reflect the range of possible experiences across individual dogs.

Each case of HCC is unique, and prognosis should be considered in the context of the individual patient, including tumor characteristics, overall health, and available treatment options.

Discussing Prognosis with Your Veterinarian

Because prognosis can vary significantly between cases, it is important to discuss your dog’s individual situation with your veterinary team. Your primary veterinarian or veterinary oncologist can help interpret diagnostic findings and explain how they may relate to your dog’s specific condition.

You may find it helpful to prepare questions in advance and discuss factors such as treatment options, expected outcomes, and quality of life. For guidance, see our resources on preparing for veterinary appointments and HCC-specific appointments.